CD274 and Miyoshi myopathy: While the PD-1/PD-L1 axis is a promising avenue of treatment in most cancers, clinical assays in MM combining those checkpoint inhibitors and IMiDs have been underwhelming and have been discontinued (see the NTC02579863, NTC02576977, NCT02726581 and NCT02431208 clinical assays [93,94]).